BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32914001)

  • 1. Case of Basal Cell Carcinoma of the Prostate Successfully Treated Before and After a
    Grossman JE; Wu Y; Ye H; Bhatt RS
    JCO Precis Oncol; 2018; 2():. PubMed ID: 32914001
    [No Abstract]   [Full Text] [Related]  

  • 2. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer.
    Singer CF; Rappaport-Fuerhauser C; Sopik V; Narod SA
    Clin Genet; 2015 Aug; 88(2):187-9. PubMed ID: 25112434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer progression and survival in BRCA2 mutation carriers.
    Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
    J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of BRCA2 mutation on localized prostate cancer.
    Taylor RA; Fraser M; Rebello RJ; Boutros PC; Murphy DG; Bristow RG; Risbridger GP
    Nat Rev Urol; 2019 May; 16(5):281-290. PubMed ID: 30808988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
    Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
    Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 mutation in Icelandic prostate cancer patients.
    Sigurdsson S; Thorlacius S; Tomasson J; Tryggvadottir L; Benediktsdottir K; Eyfjörd JE; Jonsson E
    J Mol Med (Berl); 1997 Oct; 75(10):758-61. PubMed ID: 9383000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired multiple secondary
    Tao H; Liu S; Huang D; Han X; Wu X; Shao YW; Hu Y
    Am J Transl Res; 2020; 12(2):612-617. PubMed ID: 32194909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
    Kirchhoff T; Kauff ND; Mitra N; Nafa K; Huang H; Palmer C; Gulati T; Wadsworth E; Donat S; Robson ME; Ellis NA; Offit K
    Clin Cancer Res; 2004 May; 10(9):2918-21. PubMed ID: 15131025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
    Jenzer M; Keß P; Nientiedt C; Endris V; Kippenberger M; Leichsenring J; Stögbauer F; Haimes J; Mishkin S; Kudlow B; Kaczorowski A; Zschäbitz S; Volckmar AL; Sültmann H; Jäger D; Duensing A; Schirmacher P; Hohenfellner M; Grüllich C; Stenzinger A; Duensing S
    Cancer Immunol Immunother; 2019 Oct; 68(10):1621-1633. PubMed ID: 31549213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
    van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
    J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of BRCA2 gene mutation and prognosis as well as variant genes in invasive urothelial carcinoma of the bladder.
    Kuang S; Li H; Feng J; Xu S; Le Y
    Cancer Biomark; 2019; 25(2):203-212. PubMed ID: 31045513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    Kosaka T; Hongo H; Aimono E; Matsumoto K; Hayashida T; Mikami S; Nishihara H; Oya M
    Pathol Int; 2019 Dec; 69(12):715-720. PubMed ID: 31631483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
    Cui M; Gao XS; Gu X; Guo W; Li X; Ma M; Qin S; Qi X; Xie M; Peng C; Bai Y
    Oncotarget; 2017 Jun; 8(25):40222-40232. PubMed ID: 28410213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.